Zymeworks raises 2026 guidance after closing Theravance acquisition

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to Zymeworks raises 2026 guidance after closing Theravance acquisition

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

September 28, 2026 6:00 AM EDT

Acquisition diversifies durable cash flows and advances Zymeworks strategy to build a productive R&D company with a growing portfolio of revenue-generating assetsYUPELRI® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRRZymeworks to retain existing commercial organization supporting YUPELRI hospital promotionThe Company expects total revenue, including collaboration revenue from YUPELRI, for 2026 to be between $278 million and $292 million and 2026 Adjusted EBITDA to be between $114 million and $128... More